Related references
Note: Only part of the references are listed.Design of Tumor Biomarker-Monitoring Trials: A Proposal by the European Group on Tumor Markers
Gyorgy Soletormos et al.
CLINICAL CHEMISTRY (2013)
Targeting Adjuvant Chemotherapy: A Good Idea That Needs to Be Proven!
Daniel F. Hayes
JOURNAL OF CLINICAL ONCOLOGY (2012)
Publication of Tumor Marker Research Results: The Necessity for Complete and Transparent Reporting
Lisa M. McShane et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Biospecimen Reporting for Improved Study Quality (BRISQ)
Helen M. Moore et al.
CANCER CYTOPATHOLOGY (2011)
Biospecimen Reporting for Improved Study Quality (BRISQ)
Helen M. Moore et al.
JOURNAL OF PROTEOME RESEARCH (2011)
Biomarker studies: a call for a comprehensive biomarker study registry
Fabrice Andre et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
Genomic Medicine Genomics and Drug Response
Liewei Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomized Trials
Kenneth F. Schulz et al.
ANNALS OF INTERNAL MEDICINE (2010)
Reporting of prognostic studies of tumour markers: a review of published articles in relation to REMARK guidelines
S. Mallett et al.
BRITISH JOURNAL OF CANCER (2010)
AACR-FDA-NCI Cancer Biomarkers Collaborative Consensus Report: Advancing the Use of Biomarkers in Cancer Drug Development
Samir N. Khleif et al.
CLINICAL CANCER RESEARCH (2010)
Randomized Clinical Trials With Biomarkers: Design Issues
Boris Freidlin et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
Research at the interface of industry, academia and regulatory science FOREWORD
William B. Mattes et al.
NATURE BIOTECHNOLOGY (2010)
MENU LABELING: KNOWLEDGE FOR A HEALTHIER AMERICA
Tamara Schulman
HARVARD JOURNAL ON LEGISLATION (2010)
The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP Working Group
Steven M. Teutsch et al.
GENETICS IN MEDICINE (2009)
American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy
Carmen J. Allegra et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers
Richard M. Simon et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Is there a role for circulating tumor cells in the management of breast cancer?
Daniel F. Hayes et al.
CLINICAL CANCER RESEARCH (2008)
Development of the 21-gene assay and its application in clinical practice and clinical trials
Joseph A. Sparano et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
American society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer
Lyndsay Harris et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
[Anonymous]
JOURNAL OF ONCOLOGY PRACTICE (2007)
Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer - An economic analysis based on prognostic and predictive validation studies
Gary H. Lyman et al.
CANCER (2007)
Uses and abuses of tumor markers in the diagnosis, monitoring, and treatment of primary and metastatic breast cancer
N. Lynn Henry et al.
ONCOLOGIST (2006)
Clinical trial designs for predictive marker validation in cancer treatment trials
DJ Sargent et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Share Paper
